Corpus overview


Overview

MeSH Disease

Asthenia (5)

Infections (4)

Fever (4)

Dyspnea (4)

Cough (4)


Human Phenotype

Asthenia (5)

Fever (4)

Dyspnea (4)

Cough (4)

Pneumonia (2)


Transmission

Seroprevalence
    displaying 1 - 5 records in total 5
    records per page




    Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: a retrospective cohort study

    Authors: Roberto de la Rica; Marcio Borges; Maria Aranda; Alberto del Castillo; Antonia Socias; Antoni Payeras; Gemma Rialp; Lorenzo Socias; Lluis Masmiquel; Marta Gonzalez-Freire

    doi:10.1101/2020.05.07.20094987 Date: 2020-05-11 Source: medRxiv

    OBJECTIVE To describe the clinical characteristics and epidemiological features of severe (non-ICU) and critically patients (ICU) with COVID-19 at triage, prior hospitalization, in one of the main hospitals in The Balearic Islands health care system. DESIGN Retrospective observational study SETTING Son Llatzer University Hospital in Palma de Mallorca (Spain) PARTICIPANTS Among a cohort of 52 hospitalized patients as of 31 March 2020, 48 with complete demographic information and severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) positive test, were analyzed. Data were collected between March 15th, 2020, and March 31th 2020, inclusive of these dates. MAIN OUTCOMES Clinical, vital signs and routine laboratory outcomes at the time of hospitalization, including symptoms reported prior to hospitalization. Demographics and baseline comorbidities were also collected. Mortality was reported at the end of the study. RESULTS 48 patients (27 non-ICU and 21 ICU) resident in Mallorca, Spain (mean age TRANS, 66 years, [range, 33-88 years]; 67% males TRANS) with positive SARS-CoV-2 infection MESHD were analyzed. There were no differences in age TRANS or sex among groups (p >.05). Initial symptoms included fever MESHD fever HP (100%), coughing MESHD coughing HP (85%), dyspnea MESHD dyspnea HP (76%), diarrhea MESHD diarrhea HP (42%) and asthenia MESHD asthenia HP (21%). The majority of patients in this case series were hospitalized because of low SpO2 (SpO2 below 90%) and presentation of bilateral pneumonia MESHD pneumonia HP (94%) at triage. ICU patients had a higher prevalence SERO of dyspnea MESHD dyspnea HP compared to non-ICU patients (95% vs 61%, p = .022). Acute respiratory syndrome MESHD (ARDS) was presented in 100% of the ICU-patients. All the patients included in the study required oxygen therapy. ICU-patients had lymphopenia MESHD lymphopenia HP as well as hypoalbuminemia MESHD hypoalbuminemia HP. Inflammatory markers such as lactate dehydrogenase (LDH), C-reactive protein (CRP), and procalcitonin were significantly higher in ICU patients compared to non-ICU (p < .001).Lower albumin levels were associated with poor prognosis measured as longer hospital length (r= -0.472, p

    Abdominal symptoms HP as an initial manifestation of COVID-19 infection MESHD: Report of two cases

    Authors: PATRÍCIA YOKOO; Eduardo Kaiser Ururahy Nunes Fonseca; Marcelo Oranges Filho; Rodrigo Caruso Chate; Gilberto Szarf; Ronaldo Hueb Baroni

    doi:10.21203/rs.3.rs-28198/v1 Date: 2020-05-09 Source: ResearchSquare

    The novel coronavirus (COVID-19) pandemic started in December 2019 in Wuhan (Hubei, China) and spread rapidly; therefore, it is essential to detect the disease MESHD at an early stage and immediately isolate the infected patients [1]. The most common symptoms of COVID-19 infection MESHD include fever MESHD fever HP, asthenia MESHD asthenia HP, cough MESHD cough HP and dyspnea MESHD dyspnea HP [2]. However, some patients are asymptomatic TRANS from the respiratory symptoms, and may only present abdominal manifestations as an initial finding, what creates a diagnostic challenge.We describe two cases with diagnostic confirmations of COVID-19 who showed up at the Emergency MESHD Department with abdominal symptoms HP before presenting respiratory manifestations, and who had their initial suspicion based on the findings of the thoracoabdominal transition, demonstrating the importance of an adequate assessment of the lung base images.

    Pre-Exposure Prophylaxis During COVID-19 Pandemic: Can PrEP Prevent Flu-Like Symptoms?

    Authors: Danilo Euclides Fernandes; Paulo Roberto Abrão Ferreira; Gianna Mastroianni Kirsztajn

    doi:10.21203/rs.3.rs-27798/v1 Date: 2020-05-08 Source: ResearchSquare

    Background: Considering speculations on an eventual contribution of antiretroviral drugs to treat novel coronavirus, PrEP regular use may provide useful information and clarify its role in preventing flu-like symptoms.Objective: To identify risk and/or protective factors against flu-like symptoms during COVID-19 pandemic among PrEP regular users.Methods: Phone call interview or digital investigation (through WhatsApp® or e-mail) about PrEP regular use during the novel coronavirus pandemic, social distancing, exposure to suspected or confirmed cases TRANS of COVID-19 and recent flu-like symptoms.Findings: Among 108 individuals, the majority were cisgender, white, and gay men. Although most of the individuals were in social distancing (68,52%), they did not stop taking PrEP (75,93%). Fewer people had had contact with suspected or confirmed cases of COVID-19 (12,04%), but some did have flu-like symptoms the month before the interview (27,78%) including rhinorrhea HP (56,67%), cough MESHD cough HP (53,33%), asthenia MESHD asthenia HP (50,00%) and headache MESHD headache HP (43,33%). Also, PrEP regular use was a protective factor against flu-like symptoms (OR = 0.26, 95% CI 0.07-0.96, p = 0.04) and was associated with social distancing adherence (OR = 7.2, 95% CI 2.74-19.02, p < 0.001).Conclusion: In our sample, regular use of PrEP was a protective factor against flu-like symptoms and was related to the accomplishment of social distancing during the COVID-19 pandemic in São Paulo, Brazil. 

    Clinical features of coronavirus disease MESHD 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury MESHD

    Authors: Angel Gil-Agudo; Miguel Rodriguez-Cola; Irena Jimenez-Velasco; Francisco Gutierrez-Henares; Elisa Lopez-Dolado; Claudia Gambarrutta-Malfatti; Eduardo Vargas-Baquero

    doi:10.1101/2020.04.20.20072918 Date: 2020-04-24 Source: medRxiv

    Study design: Cohort study of patients with spinal cord injury MESHD (SCI) Objectives: To describe the clinical and analytical features of a Covid-19 infected cohort with SCI to contribute new knowledge for a more accurate diagnosis and to outline prevention measures. Setting: This study was conducted at the National Hospital for Paraplegics (Toledo, Spain). Methods: A cohort analysis of seven patients with SCI infected by Covid-19 was carried out. Diagnosis was confirmed with reverse transcriptase polymerase chain reaction (RT-PCR) of nasal exudate or sputum samples. Clinical, analytical and radiographic findings were registered. Results: RT-PCR detected COVID-19 infection MESHD in all patients, affecting males TRANS and people with a cervical level of injury more often (5 out 7). The average delay for diagnostic confirmation was 4 days (interquartile range, 1-10). Fever MESHD Fever HP was the most frequent symptom (6 out of 7). The second most common symptom was asthenia MESHD asthenia HP (4 out of 7), followed by dyspnea MESHD dyspnea HP, cough MESHD cough HP and expectoration (3 out of 7 for each symptom). The MEWS score for Covid-19 severity rating was classified as severe in 5 out of 7. All but one patient showed radiological alterations evident in chest X-Rays at the time of diagnosis. All patients recovered gradually. Conclusion: Our patients with SCI and Covid-19 infection MESHD exhibited fewer symptoms than the general population. Furthermore, they presented similar or greater clinical severity. The clinical evolution was not as pronounced as had been expected. This study recommends close supervision of the SCI population to detect early compatible signs and symptoms MESHD of Covid-19 infection MESHD.

    SARS-CoV-2/COVID-19 and Advances in Developing Potential Therapeutics and Vaccines to Counter this Emerging Pandemic Virus – A Review

    Authors: Ali A. Rabaan; Shamsah H. Al-Ahmed; Ranjit Sah; Ruchi Tiwari; Mohd. Iqbal Yatoo; Shailesh Kumar Patel; Mamta Pathak; Yashpal Singh Malik; Kuldeep Dhama; Karam Pal Singh; D. Katterine Bonilla-Aldana; Shafiul Haque; Alfonso J. Rodriguez-Morales

    id:10.20944/preprints202004.0075.v1 Date: 2020-04-07 Source: preprints.org

    A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease MESHD (COVID-19), first detected in Wuhan City, Hubei Province, China has resulted in an outbreak in China which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 175 countries while affecting nearly 500,000 persons and causing more than 22,000 human deaths MESHD, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever MESHD fever HP, dyspnea MESHD dyspnea HP, asthenia MESHD asthenia HP and pneumonia MESHD pneumonia HP, thrombocytopenia MESHD thrombocytopenia HP and the severely infected patients succumb to the disease MESHD. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection MESHD and evolution, develop effective therapeutics, antiviral drugs and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. Till date, no clinically proclaimed, proven therapeutic antibodies SERO or specific drugs and therapeutics, and vaccines have turned up. Several molecular diagnostic tests such as Real Time-PCR, isothermal loop-mediated amplification of coronavirus (i-LACO), full genome analysis by next-generation sequencing (NGS), multiplex nucleic acid amplification, and microarray-based assays are in use currently for the laboratory confirmation of this CoV infection MESHD. In this review article, we describe the basic molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection MESHD, which would help in valid countering of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.